Telcagepant does not reduce exercise tolerance in patients with exercise induced myocardial ischemia

Ho A.P.¹ , Chaitman B.R.² , Behm M.O.¹ , Rowe J.F.¹ , Palcza J.S.¹ , Laethem T.³ , Heirman I.³ , Panebianco D.L.¹ , Moiseev V.S. ⁴ , Martsevich S.Y.⁵ , Free A.L.⁶ , Bittar N.⁷ , Chrysant S.G.⁸ , Kobalava Z.D. ⁴ , Ho T.W.¹ , Chodakewitz J.A.¹ , Murphy M.G.¹ , Blanchard R.L.¹

JOURNAL OF HEADACHE AND PAIN

SPRINGER-VERLAG ITALIA SRL

Английский

Опубликовано

11

2010

• ¹ Merck & Co Inc, N Wales, PA USA
• ² St Louis Univ, Sch Med, Div Cardiol, St Louis, MO USA
• ³ MSD, Brussels, Belgium
• ⁴ Russian Peoples Friendship Univ, Ctr Appl Clin Pharmacol, Moscow, Russia
• ⁵ FGU State Sci Res Ctr Prophylact Med Rosmedtechno, Moscow, Russia
• ⁶ Pinnacle Res Grp, Anniston, AL USA
• ⁷ Gemini Sci, Madison, WI USA
• ⁸ Univ Oklahoma, Oklahoma Cardiovasc & Hypertens Ctr, Oklahoma City, OK USA

20.07.2021

20.07.2021

https://repository.rudn.ru/ru/records/article/record/74773/